Plasma concentrations of nociceptin/orphanin FQ: comparison of levels after general and neuraxial anesthesia for arthroscopic knee surgery

다국어 초록 (Multilingual Abstract)

Background: Nociceptin/orphanin FQ (N/OFQ) is an endogenous opioid heptadecapeptide. Preclinically, the pharmacologic action of N/OFQ has been characterized for the treatment of pain in non-human primates. Clinically, the pharmacologic action of N/OFQ is unclear, and concentrations have only been measured under certain clinical conditions. The aims of this study were to measure the plasma concentrations of N/OFQ in different postoperative pain states and to identify the potential relationship between postoperative pain states and N/OFQ plasma concentrations.
Methods: Two groups of 14 patients scheduled for knee arthroscopy were included in this study. Postoperative pain in the first group (IV group) was controlled by intravenous patient-controlled analgesia (IV-PCA). Postoperative pain in the second group (ES group) was controlled by epidural patient-controlled analgesia (E-PCA) or the remnant analgesic effects of spinal anesthesia. Plasma concentrations of N/OFQ were measured by enzyme-linked immunosorbent assay. Numerical rating scale (NRS) scores were recorded for all patients. Differences between the two groups with regards to plasma concentrations of N/OFQ and NRS scores were evaluated by the Mann-Whitney U-test.
Results: Plasma concentrations of N/OFQ (mean ± SD) were 70.4 ± 128.0 pg/ml in the IV group and 19.2 ± 43.4 pg/ml in the ES group. NRS scores (mean ± SD) were 3.1 ± 1.9 in the IV group and 0.5 ± 1.1 in the ES group. The differences in plasma N/OFQ concentrations between groups were not significant (P = 0.06). NRS scores were significantly lower in the ES group as compared with the IV group (P = 0.0019).
Conclusions: Plasma concentrations of N/OFQ increase in acute postoperative pain states, but are not correlated with the level of postoperative pain.

참고문헌 (Reference)

1 Lambert DG, "The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential" 7 : 694-710, 2008

2 Rizzi A, "The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13) NH2, potentiates morphine analgesia" 11 : 2369-2372, 2000

3 Podlesnik CA, "The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys" 213 : 53-60, 2011

4 Mollereau C, "Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene" 93 : 8666-8670, 1996

5 Obara I, "Spinal and local peripheral antiallodynic activity of Ro64-6198 in neuropathic pain in the rat" 116 : 17-25, 2005

6 Ambriz-Tututi M, "Role of opioid receptors in the reduction of formalin-induced secondary allodynia and hyperalgesia in rats" 619 : 25-32, 2009

7 Ko MH, "Quantitative analysis of nociceptin in blood of patients with acute and chronic pain" 13 : 1631-1633, 2002

8 Agostini S, "Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats" 141 : 292-299, 2009

9 Calo' G, "Nociceptin/orphanin FQ receptor ligands" 21 : 935-947, 2000

10 Hu E, "Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112" 148 : 107-113, 2010

11 Meunier JC, "Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor" 377 : 532-535, 1995

12 Brooks H, "Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states" 78 : 71-73, 1998

13 Baraniuk JN, "Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain" 5 : 48-, 2004

14 Ko MC, "Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys" 34 : 2088-2096, 2009

15 Ko MC, "Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys" 10 : 509-516, 2009